BRKR250117P40000
- 0.30
- 0.000.00%
Bruker Corp Newsroom
10x Genomics Secures Court Injunction Against Bruker's Sale of GeoMx Products in US
10x Genomics: Injunction Expected to Prohibit Bruker From Making, Using, Selling or Offering to Sell in U.S. GeoMx Digital Spatial Profiler and Associated Instruments, Reagents and Services for RNA and Protein Detection >BRKR
Reported Earlier, Delaware Jury Awards 10x Genomics $31.7M In Patent Case Against NanoString; Permanent Injunction On GeoMx Takes Effect January 10, 2025, With Royalties For Existing Installations; Additional Rulings On CosMx Expected Spring 2025
Bruker Adds Another 1.2 GHz NMR System in Switzerland, Stock Climbs
Guggenheim Initiates Bruker Corp(BRKR.US) With Buy Rating, Announces Target Price $72
Bruker Reveals 1.2 GHz NMR Spectrometer At Swiss High-field NMR Facility
Bruker Announces 1.2 GHz NMR Spectrometer at Swiss High-field NMR Facility
Bruker Initiated at Buy by Guggenheim
Express News | Bruker Corp : Guggenheim Initiates Coverage With Buy Rating; Target Price $72
Unusual Options Activity: BRKR, TSLA and Others Attract Market Bets, BRKR V/OI Ratio Reaches 250.0
EST Dec 17th Morning Delivery - In the last two hours of trading, 9 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
Bruker (NASDAQ:BRKR) Shareholders Have Endured a 26% Loss From Investing in the Stock Three Years Ago
Unusual Options Activity: PINS, BRKR and Others Attract Market Bets, PINS V/OI Ratio Reaches 892.9
EST Dec 13th Morning Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
Bruker Is Maintained at Buy by B of A Securities
Express News | Bruker Corp : BofA Global Research Raises Price Objective to $80 From $78
BofA Securities Maintains Bruker Corp(BRKR.US) With Buy Rating, Raises Target Price to $80
Citi's 'SMID Value Creators' Stocks: GAP, CHWY, FHN, and More
Bruker Coverage Assumed by UBS at Neutral Vs Previous Rating of Buy
UBS Downgrades Bruker Corp(BRKR.US) to Hold Rating, Cuts Target Price to $66
UBS Downgrades Bruker to Neutral From Buy, Cuts Price Target to $66 From $102
Goldman Sachs Upgrades Bruker Corp(BRKR.US) to Hold Rating